Integral Health Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Integral Health Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$1.55M	–	82
2021 Q2	$1.55M	Buy	10,000 +6,667	+200%	+$968K	0.43%	60
2021 Q1	$526K	Sell	3,333 -3,334	-50%	-$702K	0.15%	66
2020 Q4	$1.55M	Sell	6,667 -5,000	-43%	-$1.16M	0.46%	52
2020 Q3	$2.56M	Buy	11,667 +6,667	+133%	+$1.63M	0.78%	48
2020 Q2	$1.42M	Sell	5,000 -1,667	-25%	-$493K	0.43%	58
2020 Q1	$1.92M	Sell	6,667 -16,333	-71%	-$4.51M	0.85%	40
2019 Q4	$6.61M	Buy	+23,000	New	+$4.99M	2.58%	18

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integral Health Asset Management's KPTI Position: Q3 2021 in Review

Integral Health Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 10,000 shares — an estimated $1.55M sold.

Integral Health Asset Management first reported a position in KPTI in Q4 2019 and held it in 7 quarters. The position peaked at $6.61M in Q4 2019. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

Integral Health Asset Management reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
Integral Health Asset Management sold 10,000 Karyopharm Therapeutics shares in Q3 2021, an estimated $1.55M.
Integral Health Asset Management first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 7 quarters.
Integral Health Asset Management's Karyopharm Therapeutics position peaked at $6.61M in Q4 2019.
134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Integral Health Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.